Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726882 · ClinicalTrials.gov registry record · Phase 2
A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
A Phase 2 study of HCV Infection, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 7
- Study locations
NCT00726882: Completed Phase 2 study of HCV Infection, sponsored by AbbVie (prior sponsor, Abbott).
NCT00726882 is a Phase 2 study of HCV Infection that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00726882, a Phase 2 study of HCV Infection, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
Primary Outcome
Participants in studies M10-351 (NCT00851890) and M10-380 (NCT00696904) were analyzed for persistence of resistance-associated variants by comparing post-treatment clonal sequence data with baseline and on-treatment sequence data from M10-351 and M10-380 studies to assess amino acid changes. Phenotypic resistance to ABT-333 was assessed by calculating the fold change in half maximal effective concentration (EC50) of post-treatment samples compared with the EC50 value for the corresponding baseli
Conditions Studied
Interventions
- PROCEDURE Blood sample collection only
- DRUG ABT-333
Study Locations (7)
California
- Site Reference ID/Investigator# 17665 - Anaheim
- Site Reference ID/Investigator# 17367 - Los Angeles
- Site Reference ID/Investigator# 17672 - Los Angeles
Florida
- Site Reference ID/Investigator# 10381 - Orlando
Louisiana
- Site Reference ID/Investigator# 17667 - Baton Rouge
Texas
- Site Reference ID/Investigator# 14461 - San Antonio
Other
- Site Reference ID/Investigator# 11141 - Santurce
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00726882 record still lists
NCT00726882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with HCV Infection appearing as the primary indexed condition, and to 2 interventions - of which Blood sample collection only is the first listed.
NCT00726882 lists 7 locations in 5 states (California, Florida, Louisiana).
Frequently Asked Questions
What is clinical trial NCT00726882 about?
NCT00726882 is a clinical study titled "A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies". The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
What is the current status of trial NCT00726882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-08. Estimated completion is 2010-05.
What conditions does trial NCT00726882 study?
This clinical trial studies the following conditions: HCV Infection.
What interventions are being tested in trial NCT00726882?
The interventions under investigation include: Blood sample collection only (PROCEDURE), ABT-333 (DRUG).
Who is sponsoring clinical trial NCT00726882?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00726882 being conducted?
This trial has 7 study locations across California, Florida, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00726882's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia